Catheter associated urinary tract infections (CAUTIs) are the most frequent type of healthcare-associated infection. Roughly 15-25% of hospitalized patients have an indwelling urinary catheter during their hospital stay. Each day of in-situ catheter use increases the risk of CAUTI. Various approaches to prevent CAUTIs, including silver hydrogel coatings, have not been effective.
We, at CHAIN Antimicrobials Ltd., have designed an effective solution to prevent CAUTIs. Our lead product, Peptide-coated catheters have shown positive results in in-vitro studies and currently clinical trials are underway. Our products will offer a promising solution to the problem of ever-increasing HAIs, decreasing the morbidity and mortality as well as reducing the financial burden on healthcare resources.
- Decrease in morbidity and mortality
- Lower financial burden on healthcare resources
- Decreased number of days of hospital stay
- Improved quality of life of the inpatients
Now, take a look at the advantages of our product:
- The molecule has efficacy: Broad-spectrum antimicrobials (1-16 µg/ml)
- Safer, tested by the ISO 10993-5 (2009), & ISO 10993-12 (2012)
- Covalently linked to the surface of the catheter, no leaching
- Easy to manufacture
- In-vitro data shows efficiency against biofilm formation, which is the principal reason for CAUTIs
The Peptide-Coated-Catheters (PACs) by CHAIN Antimicrobials could thus decrease catheter-associated urinary tract infections on a global level.